| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B16.6; CDA016; CGI-39; GRIM19; GRIM-19;;NDUFA13 |
| WB Predicted band size | 17 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human NDUFA13 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于GRIM19抗体的3篇参考文献示例(文献信息为模拟示例，建议核实真实数据库)：
1. **文献名称**: **"GRIM19 suppresses STAT3 activity and induces apoptosis in cancer cells"**
**作者**: Angell JE, et al.
**摘要**: 该研究利用GRIM19抗体证实了GRIM19通过与STAT3直接相互作用抑制其转录活性，并促进癌细胞凋亡，揭示了其作为肿瘤抑制因子的机制。
2. **文献名称**: **"Downregulation of GRIM19 correlates with poor prognosis in hepatocellular carcinoma"**
**作者**: Huang SJ, et al.
**摘要**: 通过免疫组化(使用GRIM19抗体)分析肝癌组织，发现GRIM19表达下调与患者生存率降低相关，提示其可作为肝癌预后标志物。
3. **文献名称**: **"GRIM19 is essential for mitochondrial complex I assembly and cellular energy metabolism"**
**作者**: Fearnley IM, et al.
**摘要**: 研究通过Western blot(GRIM19抗体)和质谱分析，证明GRIM19是线粒体复合物I的关键组装因子，其缺失导致氧化磷酸化功能障碍。
(注：以上文献信息为示例，实际引用请通过PubMed/Google Scholar等平台核实。)
The GRIM19 (Gene associated with Retinoid-Interferon-induced Mortality 19) antibody targets a protein initially identified as a critical mediator of cell death induced by combined retinoic acid (RA) and interferon (IFN) therapy. GRIM19. encoded by the *NDUFA13* gene, serves dual roles: it functions as a nuclear pro-apoptotic protein and as an essential subunit of mitochondrial Complex I in the electron transport chain. Structurally, GRIM19 is a 15 kDa protein localized to mitochondria and nuclei. Its apoptotic activity involves interaction with STAT3. inhibiting its transcriptional activation and promoting cell death, particularly in cancer contexts.
Antibodies against GRIM19 are widely used in research to study its expression, localization, and interactions in diseases such as cancer, autoimmune disorders, and mitochondrial dysfunction. Loss or mutation of GRIM19 correlates with tumor progression, metastasis, and impaired oxidative phosphorylation. These antibodies (polyclonal or monoclonal) are validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. They help elucidate GRIM19’s role in balancing cell survival/death and metabolic regulation. Commercial antibodies are often raised against recombinant human GRIM19 protein, with specificity confirmed via siRNA knockdown or knockout controls. Research on GRIM19 continues to explore its therapeutic potential in targeting STAT3-driven malignancies and mitochondrial disorders.
×
